Deals
Boston Scientific Puts Snake Venom Unit Up for Sale
- The business could be valued at close to $1 billion in auction
- Private equity firms and rival companies have shown interest
Eastern diamondback rattlesnake
Photographer: Balint Porneczi/BloombergThis article is for subscribers only.
Boston Scientific Corp. is exploring a sale of its specialty pharmaceutical business focused on treatments for snake venom, which could fetch close to $1 billion, according to people with knowledge of the matter.
The Marlborough, Massachusetts-based medical device maker is working with advisers on the potential sale, said the people, who asked to not be identified because the matter isn’t public.